Clinical Trial: Rifaximin for Prevention of Recurrent Mild-to-moderate Ascending Cholangitis After Biliary-enteric Anastomosis

U.S., Oct. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07895433) titled 'Rifaximin for Prevention of Recurrent Mild-to-moderate Ascending Cholangitis After Biliary-enteric Anastomosis' on Oct. 19.

Brief Summary: This single-center prospective randomized controlled trial plans to recruit 60 adult patients with recurrent ascending cholangitis after biliary-enteric anastomosis. Subjects will be randomized 1:1 to the intervention group or control group. The control group receives standard treatment. The intervention group takes rifaximin tablets together with standard treatment for 3 months. We will follow participants for 3 months. The primary outcome is the number of recurrent biliary infections. We will a...